Skip to content

Efficacy of certolizumab in women with unexplained recurrent implantation failure: a double-blind randomized controlled trial (CERTIFY)

Status
Not yet recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-511869-11-00
Acronym
APHP200031
Enrollment
161
Registered
2024-11-12
Start date
Unknown
Completion date
Unknown
Last updated
2025-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult women with recurrent implantation failures (RIF)

Brief summary

Clinical pregnancy defined as the presence of cardiac activity on ultrasound scan at 5 weeks +/- 6 days of gestation (post-implantation)

Detailed description

Live-birth, Miscarriage defined as spontaneous abortion or pregnancy stop before 12 weeks of gestation (post-implantation), All adverse events distinguishing serious adverse events. We will particularly evaluate:, - multiple pregnancies, - ectopic pregnancy, - fetal abnormalities, - small for gestational age, - intrauterine growth restriction, - preeclampsia

Interventions

Sponsors

Assistance Publique Hopitaux De Paris
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Design outcomes

Primary

MeasureTime frame
Clinical pregnancy defined as the presence of cardiac activity on ultrasound scan at 5 weeks +/- 6 days of gestation (post-implantation)

Secondary

MeasureTime frame
Live-birth, Miscarriage defined as spontaneous abortion or pregnancy stop before 12 weeks of gestation (post-implantation), All adverse events distinguishing serious adverse events. We will particularly evaluate:, - multiple pregnancies, - ectopic pregnancy, - fetal abnormalities, - small for gestational age, - intrauterine growth restriction, - preeclampsia

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026